<https://helda.helsinki.fi>

Network-based modeling of herb combinations in traditional Chinese medicine

Wang, Yinyin

2021-09

Wang , Y , Yang , H , Chen , L , Jafari , M & Tang , J 2021 , ' Network-based modeling of herb combinations in traditional Chinese medicine ' , Briefings in Bioinformatics , vol. 22 , no. 5 , 106 , pp. 1-13 . <https://doi.org/10.1093/bib/bbab106>

<http://hdl.handle.net/10138/335319>
<https://doi.org/10.1093/bib/bbab106>

cc_by_nc
publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Network-based modeling of herb combinations in traditional Chinese medicine

Yinyin Wang, Hongbin Yang, Linxiao Chen, Mohieddin Jafari and Jing Tang

Corresponding author. Jing Tang, Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Finland. E-mail: jing.tang@helsinki.fi

Abstract

Traditional Chinese medicine (TCM) has been practiced for thousands of years for treating human diseases. In comparison to modern medicine, one of the advantages of TCM is the principle of herb compatibility, known as TCM formulae. A TCM formula usually consists of multiple herbs to achieve the maximum treatment effects, where their interactions are believed to elicit the therapeutic effects. Despite being a fundamental component of TCM, the rationale of combining specific herb combinations remains unclear. In this study, we proposed a network-based method to quantify the interactions in herb pairs. We constructed a protein–protein interaction network for a given herb pair by retrieving the associated ingredients and protein targets, and determined multiple network-based distances including the closest, shortest, center, kernel, and separation, both at the ingredient and at the target levels. We found that the frequently used herb pairs tend to have shorter distances compared to random herb pairs, suggesting that a therapeutic herb pair is more likely to affect neighboring proteins in the human interactome. Furthermore, we found that the center distance determined at the ingredient level improves the discrimination of top-frequent herb pairs from random herb pairs, suggesting the rationale of considering the topologically important ingredients for inferring the mechanisms of action of TCM. Taken together, we have provided a network pharmacology framework to quantify the degree of herb interactions, which shall help explore the space of herb combinations more effectively to identify the synergistic compound interactions based on network topology.

Key words: natural products; herb combinations; network modeling; Traditional Chinese medicine (TCM); formulae; network pharmacology

INTRODUCTION

The pathogenesis and progression of many complex diseases are complicated such that the therapeutic effect of a single drug may be modest and further hampered by various side effects or drug resistance mechanisms [1]. Meanwhile, the

pharmaceutical industry has begun to face the challenge of ‘more investments, fewer drugs’ in drug discovery. To reach the goal of better treatment efficacies and fewer side effects, there has been an increasing interest to investigate the synergistic effects of drug combinations [2].

Yinyin Wang is a PhD student at the University of Helsinki. Her main interests are applying network modeling and machine learning methods to explore traditional medicine.

Hongbin Yang is a postdoc at the Department of Chemistry, University of Cambridge, Cambridge, UK. He works in cheminformatics and computational toxicology.

Linxiao Chen is a postdoc at the Department of Mathematics and Statistics, University of Helsinki, Finland. He works in applied mathematics, statistics probability as well as geometry and topology.

Mohieddin Jafari is a senior researcher at the University of Helsinki, working on systems pharmacology and biological network modeling.

Jing Tang is an assistant professor at the Faculty of Medicine of the University of Helsinki and Group Leader of Network Pharmacology for Precision Medicine group. His current research interests include network pharmacology modeling for drug combinations and precision medicine.

Submitted: 20 January 2021; **Received (in revised form):** 10 March 2021

© The Author(s) 2021. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Although high-throughput phenotypic assays have been developed to screen potential drug combinations, an exhaustive search for the top hits from the huge combinatorial space arising from numerous agents remains a daunting task [3]. In contrast, computational approaches that leverage the rapid accumulation of pharmacological data may provide a cost-effective alternative to enable more systematic analyses of drug combinations. In particular, the advent of 'omics' technologies allow us to measure the drug perturbations in biological pathways and molecular interactions, resulting in an emerging systems-level approach called network pharmacology [4]. Instead of looking for one drug which acts solely on an individual target, multi-target drugs or drug combinations are more promising to achieve sustainable clinical response as many complex diseases have been shown to include multiple disease-causing genes [5–8]. In replacing the concept of 'magic bullet', this so-called network pharmacology paradigm requires accurate computational models that in many cases, can be used to predict an effective drug combination in order to perturb robustly disease phenotypes via targeting multiple pathways [9]. Ideally, such a drug combination should work synergistically to achieve stronger therapeutic effects with reduced doses of individual agents, so that the side effects may be minimized [9–11].

To understand drug combinations better, we may look into an empirical paradigm of multi-component therapeutics known as traditional Chinese medicine (TCM) to search for insights [12, 13]. Having been developed for over 3000 years, TCM is characterized by the use of herbal formulae that usually consists of two or more medicinal herbs, which are capable of systematically preventing and treating various diseases via potentially synergistic herb interactions [14, 15]. Herb pairs involve a unique combination of two specific herbs, which form the most fundamental component of a multi-herb therapy [16]. By adding more herbs, a formula may be used to treat different diseases with greater flexibility [17–19]. For instance, *Coptis chinensis* (Huang Lian, used part: rhizome) and *Evodia rutaecarpa* (Wu Zhu Yu, used part: fruit) have been used together widely as formula ZuojinWan in clinical prescriptions for treating gastric diseases as a basic herb pair [20]. Depending on the additional herbs that are mixed with *C. chinensis* and *E. rutaecarpa*, they have been used for many disease indications, including the inhibition of inflammation [21], as well as treating hypertension [22] and obesity [23].

Considering the important role of herb pairs in the development of TCM, it might be of great significance to investigate the rationale of why certain herb pairs are commonly used for treating a particular disease [24, 25]. However, there exists very limited understanding at the molecular level on how the herb pairs work synergistically to achieve stronger therapeutic effect [12, 26, 27]. One of the major bottlenecks is that herb combination is inherently more complex as herbs usually consist of multiple ingredients. Recent studies suggested that synergistic effects in herb combinations mainly rely on the interactions of their ingredients, leading to boosted treatment effects compared to single herbs [28]. One example is the cardio-protective effects by the combination of Paeonol (isolated from the root cortex of the *Paeonia moutan* [*Syn Paeonia suffruticosa*]) and Danshensu (isolated from the root of the Chinese herb *Salvia miltiorrhiza*) [29]. Another example is the combination of icariin from aerial parts of herb *Epimedium brevicornum* (Yin Yang Huo), berberin from the bark of *Phellodendron amurense* (Huang Bai) and curculigoside from rhizome of *Curculigo orchoides* (Xian Mao) in the Er-Xian decoction, which can produce synergistic effects on Osteoclastic bone resorption [30]. Furthermore, ingredients within an herb might also interact synergistically to induce pharmacological effects. One example is the interaction of ginsenoside Rb1, ginsenoside

Rg1 and ginsenoside 20(S)-protopanaxatriol found in the root of *Panax ginseng*, which can produce synergistic effects on their antioxidant activity [31]. These individual studies on specific herbs form the basis for developing a more systematic method to model the interactions among TCM herbs at the molecular level, which may hold the key to rationalize the herb combinations for future drug discovery.

Recently, network pharmacology approaches have been introduced for the study of drug interactions for a variety of diseases [32, 33]. For example, Huang et al. [34] proposed a novel tool called DrugComboRanker based on drug functional network to prioritize potential synergistic drug combinations and further validated their mechanisms of action in lung adenocarcinoma and endocrine receptor positive breast cancer. Cheng et al. [11] proposed a network-based methodology to characterize the distance between two drugs according to their target distributions in a protein–protein interaction network. They demonstrated that clinically approved drug combinations tend to have lower distance compared to random drug pairs, and for a drug pair working synergistically for a given disease, both of them need to hit the disease module but via non-overlapping network neighborhood. Furthermore, a modularity analysis of multipartite networks has suggested that network modeling might be a promising method for understanding the mechanisms of actions of traditional medicine [35]. With the great success in understanding the interaction between chemicals and diseases, network-based models warrant further studies to make sense of the rationale of TCM herb interactions.

In this study, we hypothesized that network pharmacology models on the underlying drug–target interactions behind the herb combination may provide novel insights into herb pair's mechanisms of action, which are critical for the phenotypic-based drug discovery from TCM [36–38]. We investigated the frequencies of herb pairs that appear in the common TCM herb formulas. We developed a network-based model to characterize the distance of herbs within an herb pair in a protein–protein interaction network. The model considered the interactions of herbs at the herb, ingredient and target levels, and utilized five distance metrics including the closest, shortest, separate, kernel and center methods. In addition, area under curve (AUC) of precision and recall (PR) as well as receiver operating characteristics (ROC) were used to determine the best distance metric for discriminating the most frequent herb pairs against non-existing herb pairs. Finally, we found that a commonly used herb pair tends to have smaller network distance compared to non-existing herb pairs, suggesting that herb combinations tend to achieve stronger protein–protein interactions. In addition, we found that the center ingredients of herbs tend to play important roles. In a case study of an herb pair including *Astragalus membranaceus* and *Glycyrrhiza uralensis*, we showed that their network-based distance is significantly smaller than random and further identified the center ingredients of the herb pair. Taken together, the network modeling approach provides a more systematic framework to characterize herb interactions at molecular level that may lead to the rationalization and modernization of TCM herb combinations ultimately [27].

METHODS

Collection of herb pairs

We searched for existing herbal formulae from TCMID, a manually curated TCM database [39]. TCMID is by far one of the most comprehensive TCM databases, including 46 914 prescriptions, 8159 herbs and 25 210 ingredients. The herbal formulae in TCMID

Figure 1. Workflow of the network construction for herb pairs. Top frequent herb pairs were determined from existing herbal formulas. For each herb pair, the network consists of three levels of interactions including herb-ingredient, ingredient-target and target-target interactions. The network proximity can be determined at either the ingredient level or the target level by multiple metrics including the closest, shortest, separate, kernel and center distances. We aimed to determine the network models that can separate the most frequent from the least-frequent herb pairs.

were extracted by text mining from ancient books and published articles. More importantly, TCMID supports data download service, which facilitates the effective integration of TCM data and PPI data in our study. Therefore, for allowing a more systematic analysis of the TCM herbs, we decided to use the data from TCMID. After filtering out herbs and ingredients that are lack of target information, 349 197 herb pairs were collected from 46 929 herbal formulae, including 4415 herbs, 4330 ingredients, 3171 targets, 17 753 herb-ingredient pairs as well as 25 050 ingredient-target pairs. As the same herb pair may appear in multiple herbal formulae, we considered the top 200 most frequent herb pairs with target information for both herbs (frequencies between 358 and 3846) as a positive set (Figure 1, Supplementary Figure S1). In contrast, we determined 10 000 randomly generated herb pairs, out of which we considered 9459 herb pairs that were not

observed in the actual herbal formulae as a negative control data set. Therefore, the positive set represents the common herb pairs while the negative set represents the herb pairs that are not used in any of the herbal formulae. To obtain an independent validation set, we also collected 268 herb pairs that have been considered as basic components of herbal formulae according to traditional medicine literature [14, 16, 40].

Extraction of interactions between herbs, ingredients and targets

We collected the herb-ingredient information from the TCMID. Herbs that lack ingredient information were not considered. Similarly, ingredient compounds without structural information were discarded, as they could not be modeled in the PPI network

analysis. For the remaining ingredient compounds, their targets were extracted from the STITCH database [41]. Target–target interactions were extracted from a manually curated human interactome including 243 603 PPIs and 16 677 proteins [11], which are assembled from commonly used databases including IntAct [42], InnateDB [43], PINA [44], HPRD [45], BioGRID [46], HI-II-14_Net [47, 48], PhosphositePlus [49], KinomeNetworkX [50], INstruct [51], SignaLink2.0 [52] and MINT [53]. These databases cover a wide range of protein–protein interaction data derived from experimental and computational approaches. All the interactions were denoted as undirected edges in the network.

Network proximity models of herb pairs

The herb–herb distance can be determined by considering the ingredients as the nodes, where for a pair of ingredients their distance can be further determined from their target profiles in the PPI network. Denote that $I(A) = (a_1, a_2, \dots)$ is the ingredient set for a herb A , where for an ingredient a the set of targets is $T(a) = (t_1, t_2, \dots)$. For another herb B , its ingredient set and target sets are defined similarly. We applied five measures introduced by Cheng et al. [11] to determine the network distance between two herbs, including closest, separation, shortest, kernel and center.

The closest distance is defined as:

$$d_{I(A)I(B)}^{\text{closest}} = \frac{1}{|I(A)| + |I(B)|} \left(\sum_{a \in I(A)} \min_{b \in I(B)} di(a, b) + \sum_{b \in I(B)} \min_{a \in I(A)} di(a, b) \right), \quad (1)$$

where $di(a, b)$ is the distance between two ingredient nodes in herb A and herb B , and $|I(A)|$ and $|I(B)|$ are the numbers of ingredients for herb A and B , separately. For each ingredient in herb A , we considered its distance with all the ingredient nodes in herb B , and determined the minimal distance as its closest distance. As shown in Equation (1), we determined the mean closest distance for all the ingredients in A and B , and used it as the closest distance $d_{I(A)I(B)}^{\text{closest}}$ between the two herbs.

The separation distance is defined as the closest distance between A and B , subtracted by the average closest distances within A and B :

$$d_{I(A)I(B)}^{\text{separation}} = d_{I(A)I(B)}^{\text{closest}} - \frac{d_{I(A)I(A)}^{\text{closest}} + d_{I(B)I(B)}^{\text{closest}}}{2} \quad (2)$$

The shortest distance sums up all the distances between nodes in A and B , and then normalized by the product of their sizes:

$$d_{I(A)I(B)}^{\text{shortest}} = \frac{1}{|I(A)| \times |I(B)|} \sum_{a \in I(A), b \in I(B)} di(a, b) \quad (3)$$

The kernel distance is defined as the average of exponent-based pairwise distance, normalized by their relative network sizes:

$$d_{I(A)I(B)}^{\text{kernel}} = \frac{-1}{|I(A)| + |I(B)|} \left(\sum_{a \in I(A)} \ln \sum_{b \in I(B)} \frac{e^{-(di(a,b)+1)}}{|I(B)|} + \sum_{b \in I(B)} \ln \sum_{a \in I(A)} \frac{e^{-(di(a,b)+1)}}{|I(A)|} \right) \quad (4)$$

The center distance identifies the centers of A and B as the nodes with minimal sum of distances, and then determines the distance between the two centers:

$$d_{I(A)I(B)}^{\text{center}} = di(\text{centre}_{I(A)}, \text{centre}_{I(B)}), \quad (5)$$

where

$$\text{centre}_{I(A \text{ or } B)} = \arg\min_{u \in I(A \text{ or } B)} \sum_{b \in I(B \text{ or } A)} di(b, u) \quad (6)$$

The Equations (1–6) involve the calculation of distances for two ingredients (a, b) , for which we again have five options based on their target profiles $T(a)$ and $T(b)$ including:

$$d_{T(a)T(b)}^{\text{closest}} = \frac{1}{|T(a)| + |T(b)|} \left(\sum_{i \in T(a)} \min_{j \in T(b)} dt(i, j) + \sum_{j \in T(b)} \min_{i \in T(a)} dt(i, j) \right) \quad (7)$$

$$d_{T(a)T(b)}^{\text{separation}} = d_{T(a)T(b)}^{\text{closest}} - \frac{d_{T(a)T(a)}^{\text{closest}} + d_{T(b)T(b)}^{\text{closest}}}{2} \quad (8)$$

$$d_{T(a)T(b)}^{\text{shortest}} = \frac{1}{|T(a)| \times |T(b)|} \sum_{i \in T(a), j \in T(b)} dt(i, j) \quad (9)$$

$$d_{T(a)T(b)}^{\text{kernel}} = \frac{-1}{|T(a)| + |T(b)|} \left(\sum_{i \in T(a)} \ln \sum_{j \in T(b)} \frac{e^{-(dt(i,j)+1)}}{|T(b)|} + \sum_{j \in T(b)} \ln \sum_{i \in T(a)} \frac{e^{-(dt(i,j)+1)}}{|T(a)|} \right) \quad (10)$$

$$d_{T(a)T(b)}^{\text{center}} = dt(\text{centre}_{T(a)}, \text{centre}_{T(b)}) \quad (11)$$

As we considered five distance methods that can be applied at both the target and the ingredient levels, the network proximity can be defined by an exhaustive combination of them, resulting in 25 distance models in total. For example, a model can be constructed using closest (ingredient) – closest (target) distance, defined as the closest distance for two herbs at the ingredient level:

$$d_{I(A)I(B)}^{\text{closest}} = \frac{1}{|I(A)| + |I(B)|} \left(\sum_{a \in I(A)} \min_{b \in I(B)} di(a, b) + \sum_{b \in I(B)} \min_{a \in I(A)} di(a, b) \right) \quad (12)$$

where $di(a, b)$ for ingredient a and ingredient b is:

$$d_{T(a)T(b)}^{\text{closest}} = \frac{1}{|T(a)| + |T(b)|} \left(\sum_{i \in T(a)} \min_{j \in T(b)} dt(i, j) + \sum_{j \in T(b)} \min_{i \in T(a)} dt(i, j) \right), \quad (13)$$

where $dt(i, j)$ is the shortest path length between the two targets in the PPI network [54].

Discrimination performance of the proximity distances

We utilized the area under the ROC curve (AUC) to evaluate discriminative ability of the network proximity models for separating the top-frequent herb pairs and non-observed random herb pairs. True positive rate and false positive rate were determined at different thresholds of network proximity value. To obtain a balanced data set with an equal number of positive and negative cases, we randomly selected two herbs as non-observed herb pairs from the 4415 herbs for 200 times, resulting in a set of 200 negative herb pairs for comparison. To determine the average AUC scores, we repeated the procedure 50 times. For the 268 literature-mined herb pairs (described in the section of ‘Collection of herb pairs’ as an independent validation set), we also repeatedly generated 268 random pairs as negative control.

Figure 2. Patterns of pairing for the top 10 most frequent herbs. The frequency of the herbs is shown in the top panel while the number of unique herbs that are co-administrated with them is shown in the left panel. The numbers inside the heat map show the frequencies of their pairwise combinations.

A case study on modeling the combination of *Astragalus membranaceus* and *Glycyrrhiza uralensis*

It is reported that the herb pair Huang Qi (the root of *A. membranaceus*) and Gan Cao (the root and rhizome of *G. uralensis*) can be used for liver fibrosis and cirrhosis treatment, while neither *A. membranaceus* nor *G. uralensis* shows therapeutic effects when used alone [55, 56]. Therefore, it is important to identify the synergistic interactions of the ingredients underlying the herb pair for treating liver diseases. To explore the mechanisms of the herb pair, we constructed the herb-herb network based on their ingredients and targets. We first evaluated whether the distance between *A. membranaceus* and *G. uralensis* is different from the expectation of a random herb pair. Furthermore, we identified the center ingredients that are more likely to explain the synergy of the two herbs. To explore the potential mechanism of action for liver fibrosis of center ingredients, we collected all the targets of center ingredients from STITCH and built up the minimum local PPI network for human species. All the proteins in this PPI network were used for pathway enrichment analysis using enrichr [57]. We mainly focused on the enriched Liver disease related pathways from KEGG 2019 (Human).

RESULT

Frequency of single herbs and herb pairs

There are 8159 herbs and more than 25 210 herb ingredients in the TCMID database in total. However, after filtering out

herbs and ingredients that lack target information, 349 197 herb pairs were collected from 46 929 herbal formulae, including 4415 herbs, 4330 ingredients, 3171 targets, 17 753 herb-ingredient pairs as well as 25 050 ingredient-target pairs. Most of the herb formulae (97.9%) contain less than 20 herbs, with an average of 4.93 (Supplementary Figure S1). The herbs with top 10 highest frequencies are Gan Cao (root and rhizome of *G. uralensis*, 12,518), Dang Gui (root of *Angelica sinensis*, 7417), Ren Shen (root of *P. ginseng*, 7390), Bai Zhu (5259, root of *Atractylodes macrocephala* [Syn. *Atractylis macrocephala*]), Huang Qin (4163, root of *Scutellaria baicalensis*), Fang Feng (4074, root of *Saposhnikovia divaricata* [Syn. *Ledebouriella seseloides*]), Chuan Xiong (4007, rhizome of *Ligusticum chuanxiong* [Syn. *Ligusticum wallichii*]), Fu Ling (3666, sclerotium of *Poria cocos*), Chen Pi (3650, from the dried peel of *Pericarpium Citri Reticulatae*) (Supplementary Table S1). *G. uralensis* is extensively used as a major component in the 12 518 prescriptions, supported by its various pharmacological activities including anti-inflammatory, anti-oxidative, antidiabetic, hepatoprotective and memory enhancing activities [58]. *A. sinensis* is widely applied for menstrual disorders by enhancing the blood circulation, and also has been reported to have multiple immunomodulation and anti-inflammation, as well as cardio-cerebrovascular effects [40]. *P. ginseng* is commonly used as a functional food with a long medical history, which has shown efficacy in multiple diseases, such as anti-cancer, neurodegenerative disorders, insulin resistance and hypertension. Another important effect of *P. ginseng* is maintaining homeostasis of the immune system [59–61]. All the top three most frequent herbs

Figure 3. Network distances for the top herb pairs when comparing with random herb pairs. 'I' stands for the ingredient-level distance methods and 'T' stands for the target-level distance methods.

tend to activate the immune system, suggesting the importance of activating the immune system when prescribing TCM. This observation is consistent with the TCM theory, where these herbs are usually called tonifying (adjuvant) herbs that supplement and strengthen the treatment effects in addition to the major herbs.

These high-frequency herbs also tend to show higher chances to be combined with the other herbs (Figure 2). For example, *P. ginseng* and *G. uralensis* appear together in 3846 of 46 929 herbal formulae, followed by the pair of *A. sinensis* and *G. uralensis* that are co-administered in 2907 herbal formulae. However, the majority of the 349 197 herb pairs (99.4%) occurred in less than 100 herbal formulae. Only 163 herb pairs of the remaining 1950 (0.6%) herb pairs showed a frequency higher than 500 (Supplementary Figure S2).

As shown in Supplementary Figure S2, there is a sharp decrease of herb pair frequency after 200. Therefore, we considered those herb pairs with frequency larger than 200 to be the top herb pairs. In the following analyses, we focused on these top herb pairs and searched for their target and ingredient information (Supplementary Table S2). These herb pairs involve 61 unique herbs, for which the average number of ingredients is 16.80. There is at least one common ingredient for 43% (86) of the top 200 herb pairs, while only 2.08% of randomly generated herb pairs share at least one ingredient (Supplementary Figure S3). Use of common ingredients tends to be a strategy of TCM

prescription, as it was found that synergistic effects may be achieved by affecting the same pathways with common or similar compounds [62]. For example, Qiang Huo (the rhizome or root part of *Notopterygium incisum*) and Du Huo (the root part of *Angelica pubescens* f. *biserrata*) share 10 common ingredients (including *gamma-amin.yri.*, *camphor*, *columbianetin*, *guaio*, *guanidinium*, *isoimperatorin*, *isopimpinellin*, *nodakenin*, *scopoletin* and *osthole*) and have appeared in 522 herbal formulas. At the same time, different ingredients in these herb pairs may play various roles, such as optimization of pharmacodynamics and/or pharmacokinetics to improve therapeutic efficacy and/or reduce toxicity and adverse reactions [17], which can be explained by the 'Jun-Chen-Zuo-Shi' theory in TCM system [63]. For example, the combination of *cacalol* from plant *Cacalia delphinifolia* and *paclitaxel* extracted from the yew trees can significantly suppress tumor growth and overcome chemo-resistance [64].

Network distance for top-frequent herb pairs

We modeled the interactions for an herb pair at two levels including the ingredient and the target levels. For each level, we considered five distance methods including closest, separation, shortest, kernel and center. In the next step, we examined all combinations of distance metrics in both levels, resulting in 25 (5*5) distance models in total. We focused on the top 200 most frequent herb pairs and determined their network-based

Table 1. Comparing the network proximity models. The P-values are determined by the difference between the top 200 herb pairs and random herb pairs. Distances 1, 2, 3, 4 are the average distance for top 200 herb pairs, top 10 000 herb pairs, top non-overlapping 114 herb pairs and random herb pairs, respectively

Ingredient-level distance	Target-level distance	Distance 1	Distance 2	Distance 3	Distance 4	P-value	AUROC	AUPRC
Center	Shortest	1.92	2.09	1.81	2.41	2.50E-28	0.85	0.87
Center	Separation	0.32	0.04	0.47	0.48	9.91E-28	0.87	0.87
Closest	Center	1.61	1.78	1.46	2.06	4.39E-24	0.84	0.84
Center	Kernel	2.91	3.08	2.78	3.36	1.87E-23	0.82	0.83
Separation	Kernel	0.5	0.63	0.18	1.7	6.36E-22	0.73	0.78
Separation	Shortest	0.34	0.44	0.11	1.24	2.11E-21	0.73	0.79
Closest	Closest	1.77	1.92	1.57	2.16	1.14E-20	0.81	0.8
Closest	Separation	0.02	0.18	0.24	0.56	1.30E-18	0.81	0.81
Center	Closest	1.67	1.84	1.53	2.13	1.82E-18	0.79	0.79
Separation	Center	0.43	0.53	0.2	1.12	3.58E-16	0.73	0.79
Closest	Kernel	3.13	3.23	3	3.4	3.93E-16	0.77	0.78
Center	Center	1.62	1.75	1.49	2.05	1.76E-13	0.69	0.79
Closest	Shortest	2.22	2.31	2.12	2.47	8.31E-13	0.74	0.76
Separation	Closest	0.63	0.67	0.33	1.22	1.11E-11	0.71	0.76
Kernel	Center	3.04	3.06	3.03	3.14	0.009391	0.56	0.67
Kernel	Separation	1.52	1.55	1.47	1.68	0.029083	0.52	0.64
Shortest	Center	2.1	2.1	2.1	2.16	0.126387	0.48	0.62
Shortest	Separation	0.63	0.64	0.61	0.71	0.238476	0.48	0.61
Kernel	Closest	3.21	3.22	3.18	3.24	0.337705	0.5	0.64
Separation	Separation	0.46	0.46	0.3	0.51	0.358257	0.46	0.58
Kernel	Kernel	4.46	4.47	4.45	4.47	0.463986	0.47	0.62
Kernel	Shortest	3.53	3.54	3.53	3.54	0.488536	0.47	0.61
Shortest	Kernel	3.49	3.49	3.49	3.48	0.503392	0.45	0.6
Shortest	Closest	2.26	2.26	2.26	2.26	0.503841	0.45	0.6
Shortest	Shortest	2.56	2.56	2.56	2.55	0.51079	0.45	0.6

distances, as compared to randomly selected herb pairs. We found that the average network distance of the top herbs pairs is mostly less than the average distance of random herb pairs, with statistical significance in 16 of the 25 distance models (P-value < 0.05) (Figure 3, Table 1). For example, the center-separation model showed the best performance to differentiate the top herb pairs from random pairs, with a difference of 0.489 (P-value = 9.91E-28, t-test). As the herb-herb network is constructed based on their interactions in ingredients and targets, a shorter distance therefore indicates that herb pairs tend to affect similar pathways in order to produce synergistic effects. We also examined the likelihood of a top-frequent herb pair sharing the same ingredients, which might explain why they have shorter distance. These shared ingredients may contribute partly to the closer distances of the herb pairs.

We found that 114 out of the 200 herb pairs did not share any common ingredients, while a few herb pairs ($n=15$) shared more than three ingredients (Supplementary Figure S3). However, when we considered the 114 herb pairs that did not share any common ingredients, we still found that their distances are significantly lower than that for random herb pairs (Supplementary Figure S4). This result suggested that in addition to the common ingredients, target interactions from different ingredients within an herb pair remain a major mechanism of action to affect functionally related disease pathways.

Discrimination performance of the distance metrics

To evaluate the discrimination power of the network models, we determined the ROC curve and PR curve using the top-frequent

herb pairs as positive cases and random herb pairs as negative cases. In general, we found that the average area under the ROC curve (AUROC) and area under the PR curve (AUPRC) for the 25 distance metrics reach 0.65 and 0.72, respectively, suggesting the general validity of using the network-based distance metrics to characterize the herb-pair interactions (Table 1). We found that the top performance was achieved by two models that utilize the center distance at the ingredient level, including the center (ingredient) - separation (target) model and the center (ingredient) - shortest (target) model. The ROC curves for these two models were shown in Figure 4, confirming the superior discrimination performance.

Interestingly, we found that the five models utilizing the center distance at the ingredient level (i.e. center (ingredient) - center (target), center (ingredient) - closest (target), center (ingredient) - kernel (target), center (ingredient) - separation (target) and center (ingredient) - shortest (target)) have a better discrimination performance with mean AUROC of 0.80 and mean AUPRC of 0.83, in contrast to that of the other models (Figure 5). Different from using the other distance metric at the ingredient level, the center-based models involve the identification of the central ingredients that have a minimal sum of shortest path lengths in the herb-ingredient network. The superior performance of the center-based distance models therefore suggests that the herb-pair interactions are mainly driven by few ingredients as determined as the center nodes. These topologically important ingredients may hold the key for understanding herb pair interactions.

To validate our hypothesis, we also collected 268 known herb pairs from the literature (Supplementary Table S3). We

Figure 4. ROC curves and precision-recall curves of the (A-B) center-separation model and (C-D) the center-shortest model. Each curve is a result of one permutation while the blue curve is the average value of all the permutations.

Table 2. The center ingredients for *A. membranaceus* and *G. uralensis* determined by models with different distance methods at the target level while fixing the center distance method at the ingredient level

Center of <i>A. membranaceus</i> .	Center of <i>G. uralensis</i>	Method	Distance	Distance (top)	Distance (random)
Isorhamnetin	Glycyrrhizin; glycyrrhizic acid; 18beta-glycyrrhetinic acid; glycyrrhetinic acid; monoammonium glycyrrhizinate;	Center	1	1.62	2.05
Astragaloside	Glycyrrhizin; monoammonium glycyrrhizinate; glycyrrhizic acid	Closest	1.17	1.67	2.13
Lupeol	Isoorientin	Kernel	2.78	2.91	3.36
Calycosin	Isolico flavonol	Separation	0.33	-0.32	0.48
Lupeol	Isoorientin	Shortest	1.82	1.92	2.41

applied the 25 network models to evaluate how well these 268 known herb pairs can be separated from random pairs. In line with the previous results, we found that the distance between these known herb pairs is on average smaller than random pairs (Supplementary Table S4). The average AUROC and AUPRC across all the 25 models is 0.62 and 0.65, respectively. Furthermore, the center (ingredient) – shortest (target) model can achieve the top accuracy of AUROC 0.75 and AUPRC 0.73 (Supplementary Table S4 and Supplementary Figure S5). Notably, the 268 known herb pairs were extracted from the literature that was independent from the datasets extracted from the TCMID. The overlap between these two datasets is minimal ($n = 32$), suggesting a general valid-

ity of using network models to predict the potential of herb pairs in TCM.

The combination mechanism of herb pair *Astragalus membranaceus* and *Glycyrrhiza uralensis*

We applied our network pharmacology modeling to the study of herb pair *A. membranaceus* and *G. uralensis*. The combination of *A. membranaceus* and *G. uralensis* has shown clinical efficacy to treat liver diseases by the inhibition of notch signaling pathways [65]. It was also reported that this herb pair is able to inhibit bile acid-stimulated inflammation in chronic cholestatic liver injury mice [56] based on transcriptomics profiling [55]. However,

Figure 5. AUROC and AUPRC grouped by the distance models at the ingredient level. The statistical significance is determined by t-test.

their active ingredients and the mechanisms of action of remain poorly understood.

We retrieved 15 ingredients for *A. membranaceus* and 27 ingredients for *G. uralensis*, separately, for which three ingredients were common including *formononetin*, *clionasterol* and *clionasterol* (Supplementary Table S5). Based on the conclusion that center-based distance models tend to achieve better performance, we considered the distance for the herb pair as the distance of their center ingredients, which can be determined by five different models at the target level. We compared the herb distances with that of the top 200 herb pairs as well as the random herb pairs. We found that the herb pair distances are much smaller than that of the random herb pairs, suggesting a strong evidence for the close network proximity of the two herbs (Table 2).

By applying the center (ingredient) – closest (target) model, we found that *astramembrannin* i and *glycyrrhizin* were identified as the center of *A. membranaceus* and *G. uralensis*, separately. It was shown that *glycyrrhizin* from *G. uralensis* is effective on ferroptosis by inhibiting oxidative stress during acute liver failure [66]. Interestingly, it was reported that the synergistic anti-liver fibrosis actions by the *A. membranaceus* and *G. uralensis* can be attributed to *astragalus* saponins from *A. membranaceus* and *glycyrrhizic acid* from *G. uralensis* via TGF- β 1/Smads signaling pathway modulation [67], which is consistent with our analysis.

On the other hand, to apply the center (ingredient) – shortest (target) model, we first determined the shortest distance for each ingredient pair using the target interaction network, with which we can determine *lupeol* and *isoorientin* as the central ingredients of *A. membranaceus* and *G. uralensis*, separately. We found that the distance is 1.82, which is lower than the average (1.92) of the top herb pairs, and much lower than the average (2.41) of the random herb pairs. Interestingly, we found that the same center ingredients were also identified by the center (ingredient) – kernel (target) model. It was reported that *isoorientin* might protect alcohol induced hepatic fibrosis in rats by reducing the levels of inflammation-related pathways [68]. On the other hand, *lupeol* was known for protecting

oxidative stress-induced cellular injury of mouse liver by down-regulating anti-apoptotic Bcl-2 and upregulating pro-apoptotic Bax and Caspase 3 [69].

To illustrate further the potential combinational effects of *lupeol* and *isoorientin*, we performed pathway analysis by the targets of these two ingredients (NFE2L2, AKT1 from *isoorientin*, CTNNB1, MITF, LSS, PTEN and TP53 from *lupeol*) as well as other 10 closely associated proteins in the PPI network (Figure 6). We found that these target genes are associated with pathways related to liver disease, especially the cholesterol biosynthesis pathway, the hepatocellular carcinoma pathway, the IL-5 signaling pathway as well as the ethanol metabolism resulting in production of ROS by the CYP2E1 pathway. Therefore, it is plausible that the anti-liver fibrosis effects of herb pair *A. membranaceus* and *G. uralensis* can be attributed to the combination of *lupeol* and *isoorientin*. Taken together, this case study exemplified the feasibility and rational of applying the network model to pinpoint potential ingredient interactions and their mechanisms of action.

DISCUSSION

Understanding the mechanisms of actions of TCM requires a more systematic investigation of the herb interactions. In this paper, we proposed a novel PPI-based network model to characterize the interaction of herb pairs. To illustrate the complex nature of TCM pharmacology, we developed network distance metrics by integrating the relationships between herb, ingredients and targets. We defined the herb–herb distance based on a multiple partite network which is commonly used for biological network modeling [35]. The components of such a multi-modal network include bipartite networks of herb–ingredient and ingredient–target interactions. We considered the network proximity distance at two levels, where the nodes of the networks can be either ingredients or targets. The two-level network modeling allows the characterization of herb–herb and ingredient–ingredient interactions with greater flexibility. In this study, we have provided a panel of 25 distance models, based on which we achieved a comprehensive evaluation of herb–herb interactions. Compared to the existing methods that are mainly focusing on single herbs, our network modeling can provide more insights on the mechanisms of action of TCM herb formulae, which by principle mainly involve multi-herb combinations.

We found that commonly used herb pairs tend to have smaller network proximity distance, suggesting stronger PPI interactions between them. Moreover, using the center distance at the ingredient level, the network model tends to achieve higher accuracy of discriminating the commonly used herb pairs from random herb pairs with the best AUROC of 0.87 and AUPRC of 0.87. In general, we found that the center distance at the ingredient level improved the prediction accuracy, suggesting that ingredients that are located in the center of the herb PPI network play important roles when combined with the other herbs. These center ingredients showed a minimal sum of shortest path lengths within the herb PPI network, and therefore are more likely to activate a cascade of multiple pathways. Prioritization of these center ingredients for further functional studies shall help us understand the synergistic effects of herb pairs. Using the herb pair *A. membranaceus* and *G. uralensis* as a case study, we confirmed that its network distance was shorter than that of random herb pairs. More interestingly, the potential synergistic effects

Figure 6. PPI network and pathway enrichment of the combination of isoorientin of *G. uralensis* and lupeol of *A. membranaceus*. The targets of the two center ingredients and their associated pathways are listed.

of the center ingredient lupeol from *A. membranaceus* and the center ingredient isoorientin from *G. uralensis* were supported by the literature [67–69], which warrants more experimental validation.

On the other hand, the stronger network proximity distance between the TCM herb pairs might be due to the overlapping ingredients. Indeed, we found that 86 out of 200 top-common herb pairs shared at least one common ingredient. However, using the 114 herb pairs that do not share any common ingredients, we retained the same level of top prediction accuracy (AUROC 0.75 and AUPRC 0.73). Therefore, the strong PPI interactions were largely attributed by functionally related ingredients that may share common or similar targets. For example, the ingredient nodakenin from herb *N. incisum* and ingredient limonene from herb *A. pubescens* f. *biserrata* have five common targets, including NOS1, NOS2, NOS3, POR and MTRR. Targeting the same disease proteins with multiple ingredients is in fact an important strategy of TCM formula, as it may achieve the same level of efficacy while lowering the side effects that are caused by the high doses of single ingredient [15].

Previously, Li et al. [14] have proposed a distance-based-mutual-information (DMIM) approach to determine an interaction score between herb pairs based on their frequencies. Based on the concept proposed by DMID, many potential ingredient combinations were predicted and validated. For example, using the interaction networks, Chen et al. [70] found that the main effective ingredients in *Scabiosa comosa* and

Scabiosa tschilliensis for treating liver diseases are flavonoids which were experimentally validated. Based on the compound-target network of *Cistanche tubulosa*, the top ingredients with strong synergy potential for anti-inflammatory effect were predicted and validated by experiments in vitro [71]. Compared to DMIM, our method is based on the information at deeper molecular levels such as herb-ingredient, ingredient-target and target-target relationships, which shall provide a more refined characterization of herb-interactions. However, there are several limitations in our study to be improved in the future. For example, despite the knowledge of existing ingredients in an herb, their actual concentrations are largely unknown. Therefore, the current model treats each ingredient equally, which might lead to certain bias. Moreover, we empirically determined the common herb pairs by their frequencies of use, which might be suboptimal. In addition, there might be some combinations whose mechanisms of action may not be captured by our network methods that focus on protein-protein interactions. Furthermore, pharmaceutical evidence on the compatibility rationale of TCM has been reported [17]. Our network model may help identify the first three mechanisms of action (complementary action, neutralizing action and facilitating action) but not the pharmacokinetic potentiation. Although oral bioavailability (OB) or drug-likeness (DL) have been widely used for filtering druggable ingredients in the TCM studies [25], we did not filter the ingredients by OB and DL in our study, as OB and DL values are generally predicted

by computational models rather than from experiments [25]. Moreover, the OB and DL properties might be changed due to the interactions of the ingredients in TCM formula [17]. Although we selected the TCMID database as the main source of data, more information from other databases should be considered as a future step. For example, the TCMSP [72] database is a comprehensive network pharmacology database that consists of interactions among 499 herbs, 29 384 ingredients, 3311 targets and 837 associated diseases. Furthermore, TCMSP provides the ADME properties of these ingredients which can greatly help to filter druggable ingredients. Another limitation is the lack of target information for certain ingredients. In our model, we discarded the herbs and ingredients without any target information, as their biological roles remain unclear. In the future, computational methods, such as the similarity ensemble approach (SEA) [73], and experimental methods such as thermal proteomics profiling (TPP) [74] can help the TCM research in the aspect of targeted discovery of herb ingredients. Furthermore, in this study, we focused on the network model construction to define the relationship of herb pairs by their network distances. Our next step is to build up a more complex combination model to include higher order combinations, e.g. by calculating all the pairwise network distances among herb formula to identify the most synergistic herb combinations.

In conclusion, TCM formulae provide important resource of drug combinations in natural products. In this study, we proposed a network-based model to understand the rational of herb pairs in TCM. By qualifying the distances between herb pairs based on herb-ingredient-target interactions, the network model can identify the potential synergistic ingredients for which the mechanisms of action can be further explored. The modeling strategy itself not only helps us explore the space of herb combinations more effectively, but also can be used for prioritizing synergistic compound interactions that shall facilitate the drug discovery from TCM.

Key Points

- We proposed a network-based modeling approach to quantify the degree of interactions of herb pairs by the integration of herb-ingredient, ingredient-target and protein-protein interaction data.
- Based on a total of 46 929 herbal formulae that consists of 349 197 herb pairs, we found that frequently used herb pairs tend to have shorter distance compared to random herb pairs, suggesting that a therapeutic herb pair is more likely to affect neighboring proteins in the human interactome.
- We found that the network models based on the center distance at the ingredient level achieves the best prediction accuracy, suggesting the importance of identifying the main active ingredients from individual herbs to understand herb interactions.
- Compared to the existing methods, which are mainly focusing on single herbs, our network pharmacology approach can provide more insights on the mechanisms of action of herb combinations.

Supplementary Data

Supplementary data are available online at *Briefings in Bioinformatics*.

Funding

This work was supported by the European Research Council Starting Grant agreement (grant number 716063); the Academy of Finland Research Fellow funding (grant number 317680) and Helsinki Institute of Life Science Research Fellow funding. Y.W. was supported by the China Scholarship Council (grant number 201706740080) and the Finland EDUFI Fellowship (grant number TM-18-10928).

Data availability

Code and data are available at https://github.com/19900321/herb_pairs_netowrk_v4 and https://herbcomb.shinyapps.io/combination_table/.

References

1. Ramsay RR, Popovic-Nikolic MR, Nikolic K, et al. A perspective on multi-target drug discovery and design for complex diseases. *Clin Transl Med* 2018;**7**(1):3.
2. Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. *Expert Rev Clin Pharmacol* 2013;**6**(1):41–7.
3. Madani Tonekaboni SA, Soltan Ghorai L, Manem VSK, et al. Predictive approaches for drug combination discovery in cancer. *Brief Bioinform* 2018;**19**(2):263–76.
4. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol* 2008;**4**(11):682–90.
5. Silverman EK, Loscalzo J. Developing new drug treatments in the era of network medicine. *Clin Pharmacol Ther* 2013;**93**(1):26–8.
6. Bolognesi ML, Cavalli A. Multitarget drug discovery and polypharmacology. *ChemMedChem* 2016;**11**(12):1190–2.
7. Cardon LR, Bell JL. Association study designs for complex diseases. *Nat Rev Genet* 2001;**2**(2):91–9.
8. Kibble M, Saarinen N, Tang J, et al. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. *Nat Prod Rep* 2015;**32**(8):1249–66.
9. Tang J, Gautam P, Gupta A, et al. Applications, network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. *NPJ Syst Biol Appl* 2019;**5**(1):1–11.
10. Maljutina A, Majumder MM, Wang W, et al. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. *PLoS Comput Biol* 2019;**15**(5):e1006752.
11. Cheng F, Kovács IA, Barabási A-L. Network-based prediction of drug combinations. *Nat Commun* 2019;**10**(1):1–11.
12. Qiu J. Traditional medicine: a culture in the balance. *Nature* 2007;**448**:126–8.
13. Yuan H, Ma Q, Ye L, et al. The traditional medicine and modern medicine from natural products. *Molecules* 2016;**21**(5):559.
14. Li S, Zhang B, Jiang D, et al. Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae. *J BMC Bioinformatics* 2010;**11**(S11):S6.
15. Li S, Zhang B, Zhang N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. *BMC Syst Biol* 2011;**5**(S1):S10.
16. Wang S, Hu Y, Tan W, et al. Compatibility art of traditional Chinese medicine: from the perspective of herb pairs. *J Ethnopharmacol* 2012;**143**(2):412–23.

17. Zhou M, Hong Y, Lin X, et al. Recent pharmaceutical evidence on the compatibility rationality of traditional Chinese medicine. *J Ethnopharmacol* 2017;**206**:363–75.
18. Zhou W, Wang J, Wu Z, et al. Systems pharmacology exploration of botanic drug pairs reveals the mechanism for treating different diseases. *Sci Rep* 2016;**6**(1):1–17.
19. Ung CY, Li H, Cao ZW, et al. Are herb-pairs of traditional Chinese medicine distinguishable from others? Pattern analysis and artificial intelligence classification study of traditionally defined herbal properties. *J Ethnopharmacol* 2007;**111**(2):371–7.
20. Zhao F-R, Mao H-P, Zhang H, et al. Antagonistic effects of two herbs in Zuojin Wan, a traditional Chinese medicine formula, on catecholamine secretion in bovine adrenal medullary cells. *J Phytomedicine* 2010;**17**(8–9):659–68.
21. Chen Y, Chen W, Li R. Effect of Zuojin wan and retro-zuojin wan on inflammatory and protection factors of chills and fever gastric mucosa injury. *Chin J Integr Tradit West Med Dig* 2003;**11**:133–5.
22. Xianzheng B, Huaqin W, Yuanhui H. Effect of drug pair of *Coptis chinensis* and *Evodia rutatecarpa* on blood pressure plasma endothelin and calcitonin gene-related peptide in spontaneous hypertension rats. *Chin J Integr Med Cardio-/Cerebrovascular Dis* 2011;**9**:35.
23. Hu Y, Fahmy H, Zjawiony JK, et al. Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. *J Fitoterapia* 2010;**81**(4):259–68.
24. Tang J, Aittokallio T. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. *Curr Pharm Des* 2014;**20**(1):23–36.
25. Huang C, Zheng C, Li Y, et al. Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. *Brief Bioinform* 2014;**15**(5):710–33.
26. Stone R. Biochemistry. Lifting the veil on traditional Chinese medicine. *Science* 2008;**319**(5864):709.
27. Xu Z. Modernization: one step at a time. *Nature* 2011;**480**(7378):S90–2.
28. Kim HU, Ryu JY, Lee JO, et al. A systems approach to traditional oriental medicine. *Nat Biotechnol* 2015;**33**(3):264–8.
29. Li H, Xie Y-H, Yang Q, et al. Cardioprotective effect of paeonol and Danshensu combination on isoproterenol-induced myocardial injury in rats. *J PLoS One* 2012;**7**(11):e48872.
30. Xue L, Jiao L, Wang Y, et al. Effects and interaction of icariin, curculigoside, and berberine in er-xian decoction, a traditional chinese medicinal formula, on osteoclastic bone resorption. *Evid Based Complement Alternat Med* 2012;**490843**:2012.
31. Saw CLL, Yang AY, Cheng DC, et al. Pharmacodynamics of ginsenosides: antioxidant activities, activation of Nrf2, and potential synergistic effects of combinations. *Chem Res Toxicol* 2012;**25**(8):1574–80.
32. Fang J, Liu C, Wang Q, et al. In silico polypharmacology of natural products. *Brief Bioinform* 2018;**19**(6):1153–71.
33. Oulas A, Minadakis G, Zachariou M, et al. Systems bioinformatics: increasing precision of computational diagnostics and therapeutics through network-based approaches. *Brief Bioinform* 2019;**20**(3):806–24.
34. Huang L, Li F, Sheng J, et al. DrugComboRanker: drug combination discovery based on target network analysis. *J Bioinformatics* 2014;**30**(12):i228–36.
35. Jafari M, Wang Y, Amiryousefi A, et al. Unsupervised learning and multipartite network models: a promising approach for understanding traditional medicine. *Front Pharmacol* 2020;**11**:1319.
36. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. *Nature* 2009;**462**(7270):175–81.
37. Mohd Fauzi F, Koutsoukas A, Lowe R, et al. Chemogenomics approaches to rationalizing the mode-of-action of traditional Chinese and ayurvedic medicines. *J Chem Inf Model* 2013;**53**(3):661–73.
38. Wang X, Zhang A, Sun H. Future perspectives of Chinese medical formulae: chinmedomics as an effector. *OMICS* 2012;**16**(7–8):414–21.
39. Xue R, Fang Z, Zhang M, et al. TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis. *Nucleic Acids Res* 2012;**41**(D1):D1089–95.
40. Jin Y, Qu C, Tang Y, et al. Herb pairs containing *Angelicae sinensis* Radix (Danggui): a review of bio-active constituents and compatibility effects. *J Ethnopharmacol* 2016;**181**:158–71.
41. Szklarczyk D, Santos A, von Mering C, et al. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. *Nucleic Acids Res* 2016;**44**(D1):D380–4.
42. Orchard S, Ammari M, Aranda B, et al. The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases. *Nucleic Acids Res* 2014;**42**(D1):D358–63.
43. Breuer K, Foroushani AK, Laird MR, et al. InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation. *Nucleic Acids Res* 2013;**41**(Database issue):D1228–33.
44. Cowley MJ, Pinese M, Kassahn KS, et al. PINA v2. 0: mining interactome modules. *Nucleic Acids Res* 2012;**40**(D1):D862–5.
45. Peri S, Navarro JD, Kristiansen TZ, et al. Human protein reference database as a discovery resource for proteomics. *Nucleic Acids Res* 2004;**32**(suppl_1):D497–501.
46. Chatri-Aryamontri A, Breitkreutz B-J, Oughtred R, et al. The BioGRID interaction database: 2015 update. *Nucleic Acids Res* 2015;**43**(D1):D470–8.
47. Rolland T, Taşan M, Charleatoux B, et al. A proteome-scale map of the human interactome network. *Cell* 2014;**159**(5):1212–26.
48. Rual J-F, Venkatesan K, Hao T, et al. Towards a proteome-scale map of the human protein–protein interaction network. *Nature* 2005;**437**(7062):1173–8.
49. Hornbeck PV, Zhang B, Murray B, et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. *Nucleic Acids Res* 2015;**43**(D1):D512–20.
50. Cheng F, Jia P, Wang Q, et al. Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. *Oncotarget* 2014;**5**(11):3697.
51. Meyer MJ, Das J, Wang X, et al. INstruct: a database of high-quality 3D structurally resolved protein interactome networks. *Bioinformatics* 2013;**29**(12):1577–9.
52. Fazekas D, Koltai M, Türei D, et al. Signalink 2—a signaling pathway resource with multi-layered regulatory networks. *BMC Syst Biol* 2013;**7**(1):1–15.
53. Licata L, Briganti L, Peluso D, et al. MINT, the molecular interaction database: 2012 update. *Nucleic Acids Res* 2012;**40**(D1):D857–61.
54. Cherkassky BV, Goldberg AV, Radzik T. Shortest paths algorithms: theory and experimental evaluation. *Math Program* 1996;**73**(2):129–74.
55. Zhang G-b, Song Y-n, Chen Q-l, et al. Actions of Huangqi decoction against rat liver fibrosis: a gene expression profiling analysis. *Chinas Med* 2015;**10**(1):1–11.

56. Li W-K, Wang G-F, Wang T-M, et al. Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice. *Phytomedicine* 2019;**62**:152948.
57. Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* 2013;**14**(1):128.
58. Zhang Q, Ye M. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). *J Chromatogr A* 2009;**1216**(11):1954–69.
59. Yun T-K. *Panax ginseng*—a non-organ-specific cancer preventive? *Lancet Oncol* 2001;**2**(1):49–55.
60. Kang S, Min H. Ginseng, the 'immunity boost': the effects of *Panax ginseng* on immune system. *J Ginseng Res* 2012;**36**(4):354.
61. Tang W, Eisenbrand G. *Panax ginseng*. In: Mey CA (ed). *Chinese Drugs of Plant Origin*. Springer Berlin Heidelberg, 1992, 711–37.
62. Liu J, Liu J, Shen F, et al. Systems pharmacology analysis of synergy of TCM: an example using saffron formula. *Sci Rep* 2018;**8**(1):1–11.
63. Duan DD, Wang Z, Wang Y-Y. New omic and network paradigms for deep understanding of therapeutic mechanisms for Fangji of traditional Chinese medicine. *Acta Pharmacol Sin* 2018;**39**(6):903–5.
64. Liu W, Furuta E, Shindo K, et al. Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway. *Breast Cancer Res Treat* 2011;**128**(1):57–68.
65. Zhang X, Xu Y, Chen J-M, et al. Decoction prevents BDL-induced liver fibrosis through inhibition of notch signaling activation. *Am J Chin Med* 2017;**45**(01):85–104.
66. Wang Y, Chen Q, Shi C, et al. Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress. *Mol Med Rep* 2019;**20**(5):4081–90.
67. Zhou Y, Tong X, Ren S, et al. Synergistic anti-liver fibrosis actions of total astragalus saponins and glycyrrhizic acid via TGF- β 1/Smads signaling pathway modulation. *J Ethnopharmacol* 2016;**190**:83–90.
68. Huang QF, Zhang SJ, Zheng L, et al. Protective effect of isoorientin-2''-O- α -L-arabinopyranosyl isolated from *Gypsophila elegans* on alcohol induced hepatic fibrosis in rats. *Food Chem Toxicol* 2012;**50**(6):1992–2001.
69. Prasad S, Kalra N, Shukla Y. Hepatoprotective effects of lupeol and mango pulp extract of carcinogen induced alteration in Swiss albino mice. *Mol Nutr Food Res* 2007;**51**(3):352–9.
70. Chen Q, Wang Y, Ma F, et al. Systematic profiling of the effective ingredients and mechanism of *Scabiosa comosa* and *S. tschilliensis* against hepatic fibrosis combined with network pharmacology. *Sci Rep* 2021;**11**(1):2600.
71. Liu J, Zhu J, Xue J, et al. In silico-based screen synergistic drug combinations from herb medicines: a case using *Cistanche tubulosa*. *Sci Rep* 2017;**7**(1):16364.
72. Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. *J Chem* 2014;**6**:13.
73. Gu S, Lai L-H. Associating 197 Chinese herbal medicine with drug targets and diseases using the similarity ensemble approach. *Acta Pharmacol Sin* 2020;**41**(3):432–8.
74. Mateus A, Kurzawa N, Becher I, et al. Thermal proteome profiling for interrogating protein interactions. *Mol Syst Biol* 2020;**16**(3):e9232.